Largest pharmaceutical companies in the United States by revenue
Everything the company sold in its latest fiscal year, before any cost is taken off.
Johnson & Johnson leads the 36 pharmaceutical companies in the United States ranked by revenue, at CHF 79B, ahead of Eli Lilly (CHF 54.7B) and Merck & Co (CHF 54.5B). Figures as of 20 Nov 2026, 17:15 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 36
- First
- Johnson & JohnsonCHF 79B
- Median
- CHF 1.2B
- Combined market value
- CHF 3.16T
- Countries
- 1
- Not ranked
- 8no revenue on file
Market values as of .
United States▾
All sectors▾
Pharmaceuticals▾
| # | Company | Revenue ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Johnson & JohnsonJNJ · Health Care | CHF 79B | CHF 546.9B | CHF 227.20 | 1.39% up | 31% up | ||
| 2 | Eli LillyLLY · Health Care | CHF 54.7B | CHF 1.01T | CHF 1,136.15 | 0.25% up | 28% up | ||
| 3 | Merck & CoMRK · Health Care | CHF 54.5B | CHF 278.9B | CHF 113.15 | 1.57% up | 36% up | ||
| 4 | PfizerPFE · Health Care | CHF 52.5B | CHF 131.8B | CHF 23.13 | 0.13% up | 10% up | ||
| 5 | AbbVieABBV · Health Care | CHF 51.3B | CHF 427.8B | CHF 242.01 | 1.76% up | 20% up | ||
| 6 | Bristol-Myers SquibbBMY · Health Care | CHF 40.4B | CHF 101.8B | CHF 49.78 | 1.72% up | 26% up | ||
| 7 | Abbott LaboratoriesABT · Health Care | CHF 37.2B | CHF 151.5B | CHF 87.48 | 0.40% up | 19% down | ||
| 8 | Regeneron PharmaceuticalsREGN · Health Care | CHF 12B | CHF 80.9B | CHF 782.22 | 1.10% up | 22% up | ||
| 9 | ViatrisVTRS · Health Care | CHF 12B | CHF 18.7B | CHF 16.35 | 1.96% down | 90% up | ||
| 10 | Vertex PharmaceuticalsVRTX · Health Care | CHF 10.1B | CHF 111.5B | CHF 439.76 | 0.69% up | 22% up | ||
| 11 | ZoetisZTS · Health Care | CHF 7.9B | CHF 27.4B | CHF 67.51 | 0.38% down | 34% down | ||
| 12 | Elanco Animal HealthELAN · Health Care | CHF 4B | CHF 10.8B | CHF 21.59 | 2.09% down | 18% up | ||
| 13 | Alnylam PharmaceuticalsALNY · Health Care | CHF 3.1B | CHF 16.8B | CHF 125.42 | 1.15% up | 66% down | ||
| 14 | BioMarin PharmaceuticalBMRN · Health Care | CHF 2.7B | CHF 9.9B | CHF 51.33 | 0.37% down | 12% up | ||
| 15 | United TherapeuticsUTHR · Health Care | CHF 2.7B | CHF 19.8B | CHF 465.38 | 0.77% down | 18% up | ||
| 16 | Amneal PharmaceuticalsAMRX · Health Care | CHF 2.5B | CHF 6.2B | CHF 17.68 | 1.45% down | 79% up | ||
| 17 | Royalty PharmaRPRX · Health Care | CHF 2B | CHF 33B | CHF 57.43 | 1.11% up | 74% up | ||
| 18 | PTC TherapeuticsPTCT · Health Care | CHF 1.5B | CHF 4B | CHF 48.35 | 1.17% down | 26% down | ||
| 19 | Legend BiotechLEGN · Health Care | CHF 863M | CHF 2.5B | CHF 12.93 | 4.29% down | 43% down | ||
| 20 | Madrigal PharmaceuticalsMDGL · Health Care | CHF 803.9M | CHF 7.6B | CHF 325.46 | 2.20% down | 28% down | ||
| 21 | Ionis PharmaceuticalsIONS · Health Care | CHF 791.6M | CHF 3.8B | CHF 23.10 | 1.18% up | 64% down | ||
| 22 | Arrowhead PharmaceuticalsARWR · Health Care | CHF 695.7M | CHF 5.1B | CHF 35.87 | 2.04% down | 8% up | ||
| 23 | Corcept TherapeuticsCORT · Health Care | CHF 638.7M | CHF 5.8B | CHF 53.37 | 2.08% down | 16% down | ||
| 24 | Axsome TherapeuticsAXSM · Health Care | CHF 535.6M | CHF 5.8B | CHF 110.13 | 3.23% down | 9% down | ||
| 25 | TG TherapeuticsTGTX · Health Care | CHF 516.9M | CHF 8.2B | CHF 54.19 | 0.43% down | 103% up | ||
| 26 | InsmedINSM · Health Care | CHF 508.7M | CHF 27B | CHF 122.89 | 1.42% up | 27% down | ||
| 27 | Mirum PharmaceuticalsMIRM · Health Care | CHF 437.3M | CHF 5.4B | CHF 81.99 | 2.34% up | 35% up | ||
| 28 | BridgeBio PharmaBBIO · Health Care | CHF 421.1M | CHF 12.6B | CHF 64.76 | 1.24% down | 15% up | ||
| 29 | Travere TherapeuticsTVTX · Health Care | CHF 411.6M | CHF 3.9B | CHF 40.40 | 0.27% down | 39% up | ||
| 30 | Ligand PharmaceuticalsLGND · Health Care | CHF 224.9M | CHF 4.8B | CHF 240.82 | 0.06% up | 44% up | ||
| 31 | Rhythm PharmaceuticalsRYTM · Health Care | CHF 159.2M | CHF 6.6B | CHF 94.52 | 3.52% down | 15% up | ||
| 32 | CytokineticsCYTK · Health Care | CHF 73.8M | CHF 6B | CHF 43.40 | 0.54% up | 21% down | ||
| 33 | Protagonist TherapeuticsPTGX · Health Care | CHF 38.6M | CHF 6.7B | CHF 102.55 | 1.42% down | 45% up | ||
| 34 | Dianthus TherapeuticsDNTH · Health Care | CHF 1.7M | CHF 4B | CHF 70.59 | 0.80% down | 105% up | ||
| 35 | Spyre TherapeuticsSYRE · Health Care | CHF 0 | CHF 7.5B | CHF 79.17 | 3.33% down | 302% up | ||
| 36 | Praxis Precision MedicinesPRAX · Health Care | CHF 0 | CHF 7.2B | CHF 256.71 | 1.56% down | 83% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Revenue is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 0.8388 CHF). 8 companies have no revenue on file and are not ranked here.
Questions and answers
Which pharmaceutical companies in the United States rank first by revenue?
Johnson & Johnson (CHF 79B), Eli Lilly (CHF 54.7B) and Merck & Co (CHF 54.5B) are the top three of the 36 pharmaceutical companies in the United States ranked by revenue as of 20 Nov 2026, 17:15 UTC.
How many pharmaceutical companies in the United States are in this ranking?
36 are ranked by revenue. 8 more have no revenue on file and are left out rather than ranked at zero.
What are these pharmaceutical companies in the United States worth together?
The 36 pharmaceutical companies in the United States ranked by revenue have a combined market value of CHF 3.16T as of 20 Nov 2026, 17:15 UTC.
What does ranking by revenue measure?
Everything the company sold in its latest fiscal year, before any cost is taken off.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest pharmaceutical companies in the United States by revenue”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?country=united-states&by=revenue
Underlying data: Yahoo Finance; SEC EDGAR.